greeksoup/ stock research

Pfizer (PFE) FY2009 results: revenue $49.3 billion, up 2.0% on the year

Pfizer Inc. (PFE) reported revenue of $49.3 billion for fiscal 2009, the year ended 31 December 2009, up 2.0% on the year before. Net income was $8.6 billion, up 6.6%, and diluted earnings per share $1.23. The figures are the company's own, from the 10-K it filed with the SEC on 26 February 2010.

Revenue
$49.3 billion
+2.0% on the year
FY2007FY2009
Operating margin
n/a
FY2007FY2009
Net income
$8.6 billion
+6.6% on the year
FY2007FY2009
Diluted EPS
$1.23
+2.5% on the year
FY2007FY2009

this yearthe year beforeHover a bar for its figure.

The year in brief

Income statement (profit and loss)

$ millionFY2009FY2008FY2007On the yearLast 8 years
Revenue49,26948,29648,418+2.0%
Cost of revenue8,4598,11211,239+4.3%
Gross profit40,81040,18437,179+1.6%
Gross margin82.8%83.2%76.8%
Research and development7,8247,9458,089-1.5%
Selling, general and administrative14,75214,53715,626+1.5%
Interest expense1,233516n/a+139.0%
Pre-tax income10,6749,6949,278+10.1%
Income tax2,1451,6451,023+30.4%
Effective tax rate20.1%17.0%11.0%
Net income8,6358,1048,144+6.6%
Net margin17.5%16.8%16.8%
Diluted EPS$1.23$1.20$1.17+2.5%
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionFY2009FY2008FY2007On the yearLast 8 years
Operating cash flow16,58718,23813,353-9.1%
Capital expenditure1,2051,7011,880-29.2%
Free cash flow15,38216,53711,473-7.0%
Free cash flow margin31.2%34.2%23.7%
Cash from investing-31,272-12,835795
Cash from financing14,481-6,560-12,610
Depreciation and amortisation4,7575,0905,200-6.5%
Share-based compensation349384437-9.1%
Buybacks0.05009,994
Dividends paid5,5488,5417,975-35.0%
Diluted shares, weighted7,045m6,750m6,939m+4.4%

Balance sheet

$ millionFY2009FY2008FY2007On the yearLast 8 years
Shareholders' equity90,01457,55665,124+56.4%
Non-controlling interest432184n/a+134.8%
Debt43,2208,900n/a+385.6%
Other liabilities79,28344,508n/a+78.1%
Total liabilities and equity212,949111,148n/a+91.6%
Fixed assets22,78013,287n/a+71.4%
Goodwill42,37621,464n/a+97.4%
Intangible assets68,01517,721n/a+283.8%
Investments23,99121,609n/a+11.0%
Cash and equivalents1,9782,1223,406-6.8%
Receivables14,6458,958n/a+63.5%
Inventory12,4034,381n/a+183.1%
Other assets26,76121,606n/a+23.9%
Total assets212,949111,148n/a+91.6%

10-K for the year ended 31 December 2009, filed 26 February 2010: the filing.